| Autor: |
Karampeazis, Athanasios, Voutsina, Alexandra, Souglakos, John, Kentepozidis, Nikos, Giassas, Stelios, Christofillakis, Charalambos, Kotsakis, Athanasios, Papakotoulas, Pavlos, Rapti, Ageliki, Agelidou, Maria, Agelaki, Sofia, Vamvakas, Lambros, Samonis, George, Mavroudis, Dimitris, Georgoulias, Vassilis |
| Předmět: |
|
| Zdroj: |
Cancer (0008543X); Aug2013, Vol. 119 Issue 15, p2754-2764, 12p |
| Abstrakt: |
BACKGROUND In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC). METHODS Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. In total, 21.7% of patients in the pemetrexed arm and 23.5% of patients in the erlotinib arm had squamous cell histology, and treatment was third line in 39.2% and 46.4% of patients, respectively. The primary study endpoint was time to tumor progression (TTP). Epidermal growth factor receptor/v-Ki- ras2 Kirsten rat sarcoma viral oncogene homolog ( EGFR/ KRAS) mutation status also was investigated. RESULTS There was no difference in terms of the TTP ( P = .195), the objective response rate ( P = .469), or overall survival ( P = .986) between the 2 treatment arms. In patients who had squamous cell histology, erlotinib resulted in a superior TTP compared with pemetrexed (4.1 months vs 2.5 months, respectively; P = .006). The incidence of grade 3 and 4 neutropenia, thrombocytopenia, and asthenia was significantly higher in the pemetrexed arm, whereas the incidence of grade 3 and 4 skin rash was higher in the erlotinib arm. CONCLUSIONS Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. Cancer 2013;119:2754-2764. © 2013 American Cancer Society. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text